– MT-303 programs immune cells directly in patients; the first time an in vivo CAR has been evaluated clinically in HCC – CAMBRIDGE, Mass., November 8, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, announced today an oral presentation at the Society for Immunotherapy in Cancer […]
– MT-303 is Myeloid’s second clinical in vivo mRNA CAR program; it incorporates proprietary next-generation mRNA innovations – – MT-303 programs immune cells directly in patients; the first time an in vivo CAR has been evaluated in HCC – CAMBRIDGE, Mass., July 30, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage immunology company advancing RNA […]
-Data underlie the ongoing clinical advance of MT-302, the world’s first in vivo mRNA CAR drug development candidate- -Myeloid also highlights its pioneering CRISPR-Enabled Autonomous Transposable Element (CREATE) platform technology for precision, RNA-mediated gene editing and delivery- CAMBRIDGE, Mass, May 7, 2024 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage immunology company, today announced multiple […]
CAMBRIDGE, Mass, Feb 1 2024 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has appointed Robert Hofmeister, Ph.D., as Chief Scientific Officer (CSO). An expert in immuno-oncology, gene and cell therapy, Dr. Hofmeister brings more than 25 years of scientific leadership experience and a track record of drug discovery and early development. “As […]
CAMBRIDGE, Mass, Jan 5, 2024 – Prime Medicine, Inc. (Nasdaq: PRME) (“Prime Medicine”) and Myeloid Therapeutics, Inc. (“Myeloid”), today announced resolution of all of their outstanding disputes, signaling an end to the pending arbitrations and a positive outcome for both parties. “I am happy we have reached an amicable settlement with Myeloid. We believe resolving […]
CAMBRIDGE, Mass, December 6, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has appointed Matthew Maurer, M.D. as Chief Medical Officer. Dr. Maurer is an experienced physician-scientist with over fifteen years of clinical oncology experience as a drug developer and a principal investigator advancing multiple cancer programs through the early and late […]
MT-302 arms myeloid cells with an mRNA-encoded CAR to kill tumor cells expressing TROP2, and trigger an adaptive immune response to metastatic epithelial tumors CAMBRIDGE, Mass, September 12, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has dosed the first patient with MT-302 in a Phase 1 study for advanced or metastatic […]
Financing accelerates MT-302, the Company’s first clinical candidate for in vivo cell programming, into a Phase 1/2 clinical trial for TROP2+ solid tumors CAMBRIDGE, Mass., May 18, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, announced today the completion of a $73 million financing led by Hatteras Investment Partners, with participation from […]
Myeloid Therapeutics Presents Late-Breaking Data on Multiple Platforms at the American Association for Cancer Research (AACR) 2023 Annual Meeting CAMBRIDGE, Mass, April 17, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced its presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting, being held in Orlando, […]
Myeloid Therapeutics and New South Wales (NSW) Government in Australia Announce Collaboration to Design, Build, and Launch State-of-the-Art GMP Manufacturing Facility Dedicated to RNA Immunotherapies – NSW will invest AU $96 million to support the facility design, construction and roll-out – – Myeloid will operate the facility and bring its RNA know-how and leadership to […]